§ Mr. BarronTo ask the Secretary of State for Health if he will estimate(a) NHS expenditure on cholesterol-lowering statins, on nicotine replacement therapy and on all smoking-cessation treatment for the three years of the Comprehensive Spending Review and (b) the cost-effectiveness in cost per discounted quality-adjusted life-year saved for treatment with statins, for nicotine-replacement therapy and for the range of smoking-cessation treatments. [104640]
§ Yvette CooperThe estimated expenditure on cholesterol lowering statins for the three years of the Comprehensive Spending Review were as follows
1999: £200 million2000: £245 million2001: £275 million.In "Smoking Kills", published in December 1998, the Government announced that up to £60 million would be invested over three years in National Health Service services to help smokers to quit. £10 million has been invested in smoking cessation services in Health Action Zones in 1999–2000. No decision has yet been made about budgets for 2000–01 and 2001–02. It has been estimated that around 12.5 per cent. of the overall smoking cessation budget will be spent on one week's free nicotine replacement therapy for poorer smokers.
Estimates of cost effectiveness of these therapies exist in the literature, though not in the precise form requested. Copies of the following literature will be made available in the Library:
Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998;53 (Suppl 5, Part 2).Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon T.A, Lampe F, Sampson F, Ward S, Wannamethee G. What role for statins? A review and economic model. Health Technology Assessment 1999; Vol. 3: No. 19.